CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $4.47M, lower than 95% of all stocks globally
- PositionReturn on equity is -660%, lower than 95% of its Biotechnology peers (median -21.7%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
460.39MUSDvs all stocks (USD)
Revenue (TTM)
4.46MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.18xvs all stocks
52-Week Change
34.65%vs all stocks
Market Capitalization
460.39MUSDvs all stocks (USD)
Enterprise Value
461.83MUSDvs all stocks (USD)
Forward P/E
-5.79xvs Biotechnology peers
Price to Book (MRQ)
80.00xvs Biotechnology peers
Enterprise to Revenue
103.43xvs Biotechnology peers
Enterprise to EBITDA
-7.23xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1163.67%vs Biotechnology peers
Return on Assets (TTM)
-68.24%vs Biotechnology peers
Return on Equity (TTM)
-660.00%vs Biotechnology peers
Revenue (TTM)
4.46MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0140USDUpdated Jul 19, 2026Quarterly Revenue Growth
3.50%vs Biotechnology peers
Gross Profit (TTM)
-37.01MUSDvs all stocks (USD)
EBITDA (TTM)
-63.87MUSDvs all stocks (USD)
Net Income (TTM)
-71.67MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
3.51%vs Biotechnology peers
Operating Cash Flow (TTM)
-59.40MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-33.67MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
4.41MUSDFY2025 · Dec 31, 2025Operating Income
-62.92MUSDvs all stocks (USD)
Pre-tax Income
-67.85MUSDFY2025 · Dec 31, 2025Net Income
-67.85MUSDFY2025 · Dec 31, 2025EBIT
-62.66MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-60.27MUSDFY2025 · Dec 31, 2025Research & Development
39.75MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
27.58MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
922.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
5.19MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-67.85MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-57.67MUSDFY2025 · Dec 31, 2025Free Cash Flow
-57.85MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
18.89MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-67.85MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.39MUSDFY2025 · Dec 31, 2025Stock-based Compensation
7.71MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.31MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.23MUSDFY2025 · Dec 31, 2025Capital Expenditures
-185.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-126.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-311.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.53MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.53MUSDFY2025 · Dec 31, 2025Shares Outstanding
338.32MSharesUpdated Jul 19, 2026Float Shares
316.84MSharesUpdated Jul 19, 2026Shares Short
105.43MSharesUpdated Jul 19, 2026Short Ratio
10.98daysvs all stocks
Short % of Shares Outstanding
31.31%vs all stocks
% Held by Insiders
1.68%vs all stocks
% Held by Institutions
34.58%vs all stocks
Total Cash (MRQ)
31.86MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.0940USDUpdated Jul 19, 2026Total Debt (MRQ)
33.30MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
5.74xvs Biotechnology peers
Current Ratio (MRQ)
1.86xvs Biotechnology peers
Book Value per Share (MRQ)
0.0170USDUpdated Jul 19, 2026Total Assets
43.52MUSDvs all stocks (USD)
Total Current Assets
24.34MUSDFY2025 · Dec 31, 2025Total Liabilities
55.68MUSDFY2025 · Dec 31, 2025Total Non-current Assets
19.18MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
32.64MUSDFY2025 · Dec 31, 2025Total Current Liabilities
23.04MUSDFY2025 · Dec 31, 2025Cash
18.57MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
18.57MUSDFY2025 · Dec 31, 2025Accounts Payable
6.20MUSDFY2025 · Dec 31, 2025Short-term Debt
2.11MUSDFY2025 · Dec 31, 2025Deferred Revenue
5.91MUSDFY2025 · Dec 31, 2025Other Current Liabilities
3.39MUSDFY2025 · Dec 31, 2025Long-term Debt
31.04MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.60MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.13MUSDFY2025 · Dec 31, 2025Retained Earnings
-408.07MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-12.17MUSDvs all stocks (USD)
Treasury Stock
48.00KUSDFY2025 · Dec 31, 202552-Week Low
0.9310USDUpdated Jul 19, 202652-Week High
2.73USDUpdated Jul 19, 202652-Week Change
34.65%vs all stocks
Beta
2.18xvs all stocks
50-Day MA
1.38USDUpdated Jul 19, 2026200-Day MA
1.55USDUpdated Jul 19, 2026Avg 10-Day Volume
4.97MSharesUpdated Jul 19, 2026Avg 30-Day Volume
8.32MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.2400USDUpdated Jul 19, 2026Other Income / Expense
-664.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -660%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -6.60Industry median: -0.22Industry P5: -1.66Peers compared: 261
Debt-to-equity is 5.74×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 5.74Industry median: 0.09Industry P95: 0.88Peers compared: 261
Price-to-book is 80×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 80.00Industry median: 2.97Industry P95: 23.50Peers compared: 261
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 31,855,000Total Debt (USD): 33,296,000Debt-to-Equity: 5.74
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.77
High structural barrier to entryNotable
Barrier to Entry: 361.072
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $4.47M, lower than 95% of all stocks globallySignificant
Revenue (USD): 4,465,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Anhui Fengyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cabaletta Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Kawin Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guanhao Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yungshin Global Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Leadman Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
China High-Speed Railway Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Root, Inc. Class A Common Stock
1 interpretationPartial Recovery After Sharp Decline
Hunan Yujing Machinery Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline